Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating

Group 1: Company Performance and Financials - Novo Nordisk A/S reported third-quarter revenue of DKK 154.94 billion, reflecting a year-on-year increase of 16.1% [4] - Operating profit rose by 25%, and sales in the Diabetes and Obesity care segment increased by 16% [4] - Free cash flow reached DKK 33.6 billion, with the company returning DKK 35.6 billion to shareholders [4] Group 2: Market Strategy and Competition - Novo Nordisk announced a price cut for its obesity drugs to compete with Eli Lilly, offering a new price of $349 per month for the first two months through its NovoCare portal, which is approximately 30% lower than current self-pay pricing [3] - The self-pay cost for Ozempic 2mg will remain at $499 per month [3] Group 3: Analyst Ratings and Price Targets - Berenberg lowered its price target for Novo Nordisk to DKK 400 from DKK 425 while maintaining a Buy rating on the shares [2] - Novo Nordisk is included among the 12 Best European Dividend Stocks to Buy Now [1]